Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-23

Clinical Trial Update: Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA [Phase 3]

View source ↗

Summary

Phase 3 trial onabotulinumtoxinA for chronic post-traumatic headache was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: University of Washington | Conditions: Chronic Post Traumatic Headache | Phase 3 | Status: TERMINATED | Results posted: 2018-10-23